Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with advanced or metastatic malignancy
Received standard of care treatment for primary malignancy and standard of care treatment for relapsed cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Prior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways.
Subjects previously treated with investigational anticancer therapies less than 6 weeks prior to the first dose of Nivolumab
Subjects with an active, known, or suspected autoimmune disease
Clareo Health | An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
